| # | Title | Journal | Year | Citations |
|---|
| 1 | Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation | Value in Health | 2005 | 3,370 |
| 2 | Medication Compliance and Persistence: Terminology and Definitions | Value in Health | 2008 | 1,701 |
| 3 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force | Value in Health | 2013 | 1,657 |
| 4 | Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets | Value in Health | 2012 | 1,381 |
| 5 | Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force | Value in Health | 2011 | 1,342 |
| 6 | Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force | Value in Health | 2013 | 1,169 |
| 7 | Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies | Value in Health | 2003 | 948 |
| 8 | Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1 | Value in Health | 2011 | 822 |
| 9 | Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force | Value in Health | 2016 | 782 |
| 10 | Content Validity—Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 2—Assessing Respondent Understanding | Value in Health | 2011 | 766 |
| 11 | Content Validity—Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 1—Eliciting Concepts for a New PRO Instrument | Value in Health | 2011 | 747 |
| 12 | Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force | Value in Health | 2014 | 742 |
| 13 | An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds | Value in Health | 2018 | 692 |
| 14 | Dutch Tariff for the Five-Level Version of EQ-5D | Value in Health | 2016 | 652 |
| 15 | Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge? | Value in Health | 2004 | 647 |
| 16 | The KIDSCREEN-52 Quality of Life Measure for Children and Adolescents: Psychometric Results from a Cross-Cultural Survey in 13 European Countries | Value in Health | 2008 | 636 |
| 17 | Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2 | Value in Health | 2011 | 606 |
| 18 | Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research | Value in Health | 2016 | 589 |
| 19 | Patient-Reported Outcomes to Support Medical Product Labeling Claims: FDA Perspective | Value in Health | 2007 | 583 |
| 20 | Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report | Value in Health | 2005 | 567 |
| 21 | QALYs: The Basics | Value in Health | 2009 | 562 |
| 22 | Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report | Value in Health | 2007 | 547 |
| 23 | Equivalence of Electronic and Paper-and-Pencil Administration of Patient-Reported Outcome Measures: A Meta-Analytic Review | Value in Health | 2008 | 547 |
| 24 | Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report | Value in Health | 2015 | 539 |
| 25 | Response Burden and Questionnaire Length: Is Shorter Better? A Review and Meta-analysis | Value in Health | 2011 | 535 |
| 26 | A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases | Value in Health | 2007 | 534 |
| 27 | Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis | Value in Health | 2007 | 517 |
| 28 | Assessment of Health-Related Quality of Life in Children: A Review of Conceptual, Methodological, and Regulatory Issues | Value in Health | 2004 | 513 |
| 29 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement | Value in Health | 2013 | 513 |
| 30 | Use of Stabilized Inverse Propensity Scores as Weights to Directly Estimate Relative Risk and Its Confidence Intervals | Value in Health | 2010 | 505 |
| 31 | Literature Review of Methods to Translate Health-Related Quality of Life Questionnaires for Use in Multinational Clinical Trials | Value in Health | 2008 | 496 |
| 32 | Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1 | Value in Health | 2012 | 481 |
| 33 | Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6 | Value in Health | 2012 | 478 |
| 34 | Health-Related Quality of Life Measurement in Children and Adolescents: A Systematic Review of Generic and Disease-Specific Instruments | Value in Health | 2008 | 470 |
| 35 | Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force | Value in Health | 2016 | 437 |
| 36 | Incorporating the Patient's Perspective into Drug Development and Communication: An Ad Hoc Task Force Report of the Patient-Reported Outcomes (PRO) Harmonization Group Meeting at the Food and Drug Administration, February 16, 2001 | Value in Health | 2003 | 431 |
| 37 | Recommendations on Evidence Needed to Support Measurement Equivalence between Electronic and Paper-Based Patient-Reported Outcome (PRO) Measures: ISPOR ePRO Good Research Practices Task Force Report | Value in Health | 2009 | 430 |
| 38 | Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report | Value in Health | 2009 | 395 |
| 39 | South Korean Time Trade-Off Values for EQ-5D Health States: Modeling with Observed Values for 101 Health States | Value in Health | 2009 | 375 |
| 40 | Assessing the Direct Costs of Treating Nonvalvular Atrial Fibrillation in the United States | Value in Health | 2006 | 373 |
| 41 | What Is Sufficient Evidence for the Reliability and Validity of Patient-Reported Outcome Measures? | Value in Health | 2007 | 373 |
| 42 | Application of Rasch Analysis in the Development and Application of Quality of Life Instruments | Value in Health | 2004 | 350 |
| 43 | A Program of Methodological Research to Arrive at the New International EQ-5D-5L Valuation Protocol | Value in Health | 2014 | 341 |
| 44 | State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3 | Value in Health | 2012 | 336 |
| 45 | Recommendations for Evaluating the Validity of Quality of Life Claims for Labeling and Promotion | Value in Health | 1999 | 335 |
| 46 | PROMIS® Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains | Value in Health | 2019 | 335 |
| 47 | Estimating an EQ-5D-5L Value Set for China | Value in Health | 2017 | 330 |
| 48 | A Checklist for Retrospective Database Studies—Report of the ISPOR Task Force on Retrospective Databases | Value in Health | 2003 | 328 |
| 49 | Pediatric Patient-Reported Outcome Instruments for Research to Support Medical Product Labeling: Report of the ISPOR PRO Good Research Practices for the Assessment of Children and Adolescents Task Force | Value in Health | 2013 | 322 |
| 50 | Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3] | Value in Health | 2018 | 321 |
